21,647 Shares in Moderna, Inc. (NASDAQ:MRNA) Bought by ASR Vermogensbeheer N.V.

Key Points

• ASR Vermogensbeheer N.V. acquired a new stake in Moderna, purchasing 21,647 shares valued at approximately $614,000 during the first quarter.
• Institutional investors hold 75.33% of Moderna's stock, with significant increases from several hedge funds including Voloridge Investment Management and Federated Hermes.
• Moderna reported a loss of ($2.13) EPS for the last quarter, exceeding analyst expectations but experiencing a 41.1% decline in revenue compared to the previous year.

ASR Vermogensbeheer N.V. bought a new stake in Moderna, Inc. (NASDAQ:MRNA - Free Report) in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund bought 21,647 shares of the company's stock, valued at approximately $614,000.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Itau Unibanco Holding S.A. grew its holdings in shares of Moderna by 51.2% during the 4th quarter. Itau Unibanco Holding S.A. now owns 1,013 shares of the company's stock valued at $42,000 after purchasing an additional 343 shares during the last quarter. Costello Asset Management INC bought a new stake in shares of Moderna during the 1st quarter valued at approximately $30,000. Vega Investment Solutions bought a new stake in shares of Moderna during the 4th quarter valued at approximately $45,000. Sentry Investment Management LLC bought a new stake in shares of Moderna during the 1st quarter valued at approximately $31,000. Finally, Deseret Mutual Benefit Administrators grew its holdings in shares of Moderna by 53.3% during the 1st quarter. Deseret Mutual Benefit Administrators now owns 1,128 shares of the company's stock valued at $32,000 after purchasing an additional 392 shares during the last quarter. 75.33% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several equities analysts have issued reports on the stock. UBS Group decreased their price target on shares of Moderna from $78.00 to $70.00 and set a "buy" rating for the company in a research report on Friday, May 2nd. Bank of America decreased their price target on shares of Moderna from $26.00 to $25.00 and set an "underperform" rating for the company in a research report on Tuesday, July 22nd. William Blair restated a "market perform" rating on shares of Moderna in a research report on Monday, June 2nd. Wells Fargo & Company restated an "equal weight" rating on shares of Moderna in a research report on Sunday, July 13th. Finally, Evercore ISI set a $32.00 target price on shares of Moderna in a research report on Friday, August 1st. Four investment analysts have rated the stock with a sell rating, sixteen have given a hold rating, three have given a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, Moderna has a consensus rating of "Hold" and a consensus target price of $43.59.

Moderna Price Performance

NASDAQ:MRNA traded up $0.19 on Tuesday, reaching $25.66. 12,208,326 shares of the company's stock were exchanged, compared to its average volume of 8,260,010. Moderna, Inc. has a 52 week low of $23.15 and a 52 week high of $91.99. The stock has a fifty day simple moving average of $29.19 and a 200-day simple moving average of $29.75.

Moderna (NASDAQ:MRNA - Get Free Report) last released its quarterly earnings data on Friday, August 1st. The company reported ($2.13) EPS for the quarter, beating analysts' consensus estimates of ($2.99) by $0.86. Moderna had a negative net margin of 94.31% and a negative return on equity of 25.96%. The company had revenue of $142.00 million during the quarter, compared to analyst estimates of $116.26 million. During the same period last year, the business earned ($3.33) earnings per share. Moderna's revenue was down 41.1% compared to the same quarter last year. Equities analysts forecast that Moderna, Inc. will post -9.61 EPS for the current year.

Moderna Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.